Psychedelic-Assisted Group Therapy: A Systematic Review

References

• Baldwin, S. A., D. M. Murray, and W. R. Shadish. 2005. Empirically supported treatments or type I errors? Problems with the analysis of data from group-administered treatments. Journal of Consulting and Clinical Psychology 73 (5):924–35. doi:10.1037/0022-006X.73.5.924.
   PubMed Web of Science ®Google Scholar
• Bernard, H., G. Burlingame, P. Flores, L. Greene, A. Joyce, J. C. Kobos, M. Leszcz, R. R. MacNair-Semands, W. E. Piper, A. M. S. McEneaney, et al. 2008. Clinical practice guidelines for group psychotherapy. International Journal of Group Psychotherapy 58 (4):455–542. <Go to ISI>://WOS:000259655200002. doi:10.1521/ijgp.2008.58.4.455.
   PubMed Web of Science ®Google Scholar
• Bierer, J., and I. W. Browne. 1960. An experiment with a psychiatric night hospital. Proceedings of the Royal Society of Medicine 53:930–32.
   PubMedGoogle Scholar
• Bierer, J., and J. Buckman. 1961. Marlborough night hospital: Treatment with LSD and group therapy. Nursing Times 57:637–39.
   Google Scholar
• Blewett, D. B., and N. Chwelos. 1959. (2002 digital version). Handbook for the therapeutic use of lysergic acid diethylamide-25: Individual and group procedures. Edited by MAPS and Erowid. https://erowid.org/psychoactives/guides/handbook_lsd25.shtml.
   Google Scholar
• BMJ Editorial Board. 1938. Play therapy and child guidance. British Medical Journal 2 (4065):1150–51. https://www.ncbi.nlm.nih.gov/pubmed/20781936.
   PubMedGoogle Scholar
• Bossis, A. P. 2015. Psilocybin-generated mystical experience research: Implications for alleviating existential distress associated with a cancer diagnosis. Public lecture, UCSF Osher Center for Integrative Medicine, San Francisco, CA, October 26, 2015.
   Google Scholar
• Bowen, W. T., R. A. Soskin, and J. W. Chotlos. 1970. Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism. A follow-up study. Journal of Nervous and Mental Disease 150 (2):111–18.
   PubMedGoogle Scholar
• Bradberry, M., D. Byler, G. Gilpin, D. Host-Jablonski, and C. Brown. 2017. PANEL: UW Psilocybin Pharmacokinetics study: Study volunteers discussion. Psychedelic Science 2017, Oakland, CA, April 22, 2017.
   Google Scholar
• Burlingame, G. M., J. D. Seebeck, R. A. Janis, K. E. Whitcomb, S. Barkowski, J. Rosendahl, and B. Strauss. 2016. Outcome differences between individual and group formats when identical and nonidentical treatments, patients, and doses are compared: A 25-year meta-analytic perspective. Psychotherapy 53 (4):446–61. doi:10.1037/pst0000090.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., D. Erritzoe, E. Haijen, M. Kaelen, and R. Watts. 2018. Psychedelics and connectedness. Psychopharmacology 235 (2):547–50. doi:10.1007/s00213-017-4701-y.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., and G. M. Goodwin. 2017. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology 42 (11):2105–13. doi:10.1038/npp.2017.84.
   PubMed Web of Science ®Google Scholar
• Center for Optimal Living. 2018. Psychedelic harm reduction and exploration group. Accessed November 18, 2018. https://www.psychedelicprogram.com/psychedelic-harm-reduction-and-exploration-group.
   Google Scholar
• Cheek, F. E., H. Osmond, M. Sarett, and R. Albahary. 1966. Observations regarding the use of LSD-25 in the treatment of alcoholism. Journal of Psychopharmacology 1 (2):56–74.
   Google Scholar
• Chwelos, N., D. B. Blewett, C. M. Smith, and A. Hoffer. 1959. Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly Journal of Studies on Alcohol 20:577–90.
   PubMedGoogle Scholar
• Dobkin de Rios, M. 1972. Visionary vine: Psychedelic healing in the Peruvian Amazon. San Francisco: Chandler Publications Co.
   Google Scholar
• ERIE, Entheogenic Research Integration & Education. 2018. ERIE events page. Accessed November 18, 2018. https://erievision.org/events/.
   Google Scholar
• Erowid. 2017. Erowid reference vaults. Accessed November 7, 2018. https://www.erowid.org/references/.
   Google Scholar
• Fontana, A. E. 1961. El uso clinico de las drogas alucinógenas. Acta Neuropsiquiátrica Argentina 7 (94):1–8.
   Google Scholar
• Gasser, P. 1995. Psycholytic therapy with MDMA and LSD in Switzerland. MAPS Bulletin 5 (3):3–7.
   Google Scholar
• Gouzoulis-Mayfrank, E., F. Schneider, J. Friedrich, M. Spitzer, B. Thelen, and H. Sass. 1998. Methodological issues of human experimental research with hallucinogens. Pharmacopsychiatry 31 (S 2):114–18. doi:10.1055/s-2007-979356.
   PubMed Web of Science ®Google Scholar
• Griffiths, R., M. Johnson, W. Richards, B. Richards, R. Jesse, K. MacLean, F. Barrett, M. Cosimano, and M. Klinedinst. 2018. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology 31 (1):49-69. doi: 10.1177/0269881117731279.
   Web of Science ®Google Scholar
• Guerra-Doce, E. 2015. Psychoactive substances in Prehistoric times: Examining the archaeological evidence. Time and Mind 8 (1):91–112. doi:10.1080/1751696X.2014.993244.
   Web of Science ®Google Scholar
• Harner, M. J. 1973. Hallucinogens and shamanism. New York: Oxford University Press.
   Google Scholar
• Hausner, M., and V. Doležal. 1963. Group and individual psychotherapy under LSD. Acta psychotherapeutica et psychosomatica 11:39–59.
   PubMedGoogle Scholar
• Hausner, M., and V. Doležal. 1966. Follow-up studies in group and individual LSD psychotherapy. Activitas Nervosa Superior 8:87–95.
   PubMedGoogle Scholar
• Heim, R., and A. Hoffmann. 1958. Isolement de la Psilocybine à partir du Stropharia cubensis Earle et d’autres espèces de champignons hallucinogènes mexicains appartenant au genre Psilocybe. Comptes rendus de l’Académie des Sciences 247:557–61.
   Google Scholar
• Jensen, S. E. 1962. A treatment program for alcoholics in a mental hospital. Quarterly Journal of the Study on Alcohol 23 (2):315–20.
   PubMedGoogle Scholar
• Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22:603–20. doi:10.1177/0269881108093587.
   PubMed Web of Science ®Google Scholar
• Kenny, D. A., L. Mannetti, A. Pierro, S. Livi, and D. A. Kashy. 2002. The statistical analysis of data from small groups. Journal of Personality and Social Psychology 83 (1):126–37. doi:10.1037//0022-3514.83.1.126.
   PubMed Web of Science ®Google Scholar
• Krogel, J., G. Burlingame, C. Chapman, T. Renshaw, R. Gleave, M. Beecher, and R. Macnair-Semands. 2013. The group questionnaire: A clinical and empirically derived measure of group relationship. Psychotherapy Research: Journal of the Society for Psychotherapy Research 23:344–54. doi:10.1080/10503307.2012.729868.
   PubMed Web of Science ®Google Scholar
• Labate, B. C., and C. Cavnar. 2014. Ayahuasca shamanism in the amazon and beyond. New York: Oxford University Press.
   Google Scholar
• Labate, B. C., and C. Cavnar. 2016. Peyote: History, tradition, politics, and conservation. Santa Barbara: ABC-CLIO.
   Google Scholar
• Leary, T., R. Metzner, M. Presnell, G. Weil, R. Schwitzgebel, and S. Kinne. 1965. A new behavior change program using psilocybin. Psychotherapy 2 (2):61–72. doi:10.1037/h0088612.
   Web of Science ®Google Scholar
• Liberati, A., D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche, J. P. Ioannidis, M. Clarke, P. J. Devereaux, J. Kleijnen, and D. Moher. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700. doi:10.1136/bmj.b2700.
   PubMed Web of Science ®Google Scholar
• Mangini, M. 1998. Treatment of alcoholism using psychedelic drugs: A review of the program of research. Journal of Psychoactive Drugs 30 (4):381–418. doi:10.1080/02791072.1998.10399714.
   PubMed Web of Science ®Google Scholar
• MAPS, Multidisciplinary Assocation of Psychedelic Studies. 2018. Psychedelic Bibliography. Accessed November 7, 2018. https://maps.org/resources/psychedelic-bibliography.
   Google Scholar
• Mascher, E. 1967. Psycholytic therapy: Statistics and indications. In Neuro-psychopharmacology, ed. H. Brill, J. O. Cole, P. Denker, H. Hippins, and P. B. Bradley, 441–44. Amsterdam: Excerpta Medica Foundation.
   Google Scholar
• McRoberts, C., G. Burlingame, and M. Hoag. 1998. Comparative efficacy of individual and group psychotherapy: A meta-analytic perspective. Group Dynamics: Theory, Research, and Practice 2 (2):101–17. doi:10.1037/1089-2699.2.2.101.
   Google Scholar
• Mithoefer, M. C. 2017. A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder (Version 8.1; 22 May 2017). A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Accessed November 29, 2018. https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/TreatmentManual_MDMAAssistedPsychotherapyVersion+8.1_22+Aug2017.pdf.
   Google Scholar
• O’Brien, C. P., and R. T. Jones. 1994. Methodological issues in the evaluation of a medication for its potential benefits in enhancing psychotherapy. In Fifty years of LSD: Current status and perspectives of hallucinogens, Pletscher & Ladewig (eds.), 213–22. New York: Parthenon.
   Google Scholar
• Osmond, H., R. Albahary, F. E. Cheek, and M. Sarett. 1967. Some problems in the use of LSD 25 in the treatment of alcoholism. In The use of LSD in psychotherapy and alcoholism, ed. H. A. Abramson, 434–57. Indianapolis: Bobbs-Merrill Company, Inc.
   Google Scholar
• Pahnke, W. 1963. Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis submitted as part of Ph.D. in Religion and Society, Harvard University.
   Google Scholar
• Passie, T. 1997. Psycholytic and psychedelic therapy research 1931–1995: A complete international bibliography. Hannover: Laurentius Publishers.
   Google Scholar
• Passie, T. 2006. A history of the use of psilocybin in psychotherapy. In Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin Mushroom, ed. R. Metzner, 113–38. Rochester, Vt.: Park Street Press.
   Google Scholar
• Passie, T. 2012. Healing with Entactogens. Santa Cruz: Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Preller, K. H., L. Schilbach, T. Pokorny, J. Flemming, E. Seifritz, and F. X. Vollenweider. 2018. Role of the 5-HT2A receptor in self-and other-initiated social interaction in LSD-induced states—A pharmacological fMRI study. Journal of Neuroscience 1939–2017. doi:10.1523/JNEUROSCI.1939-17.2018.
   Web of Science ®Google Scholar
• Rucker, J. J. H., J. Iliff, and D. J. Nutt. 2017. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. doi:10.1016/j.neuropharm.2017.12.040.
   PubMed Web of Science ®Google Scholar
• Rucker, J. J. H., L. A. Jelen, S. Flynn, K. D. Frowde, and A. H. Young. 2016. Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology 30 (12):1220–29. doi:10.1177/0269881116679368.
   PubMed Web of Science ®Google Scholar
• Sabina, M., and R. G. Wasson. 1974. María Sabina and her Mazatec mushroom velada. New York: Harcourt Brace Jovanovich.
   Google Scholar
• Smart, R. G., T. Storm, E. F. Baker, and L. Solursh. 1966. A controlled study of Lysergide in the treatment of alcoholism 1. The effects on drinking behavior. Quarterly Journal of Studies on Alcohol 27 (3):469–82.
   PubMedGoogle Scholar
• Sokolik, Z., and M. Hausner. 1972. Difficulties in psychotherapy with psychodysleptics. World Journal of Psychosynthesis 4 (2):41–43.
   Google Scholar
• Spencer, A. M. 1963. Permissive group therapy with lysergic acid diethylamide. British Journal of Psychiatry Bulletin 109 (458):37–45. doi:10.1192/bjp.109.458.37.
   Web of Science ®Google Scholar
• Strauss, B., G. M. Burlingame, and B. Bormann. 2008. Using the CORE-R battery in group psychotherapy. Journal of Clinical Psychology 64 (11):1225–37. doi:10.1002/jclp.20535.
   PubMed Web of Science ®Google Scholar
• Tasca, G. A., V. Illing, A. S. Joyce, and J. S. Ogrodniczuk. 2009. Three-level multilevel growth models for nested change data: A guide for group treatment researchers. Psychotherapy Research 19 (4–5):453–61. doi:10.1080/10503300902933188.
   PubMed Web of Science ®Google Scholar
• Ucha Udabe, R., R. Kertesz, J. A. Savorgnan, and D. Mannino. 1968. LSD y Amfetaminas en psicoterapia grupal. La Semana médica, Buenos Aires 132:1131–34.
   Google Scholar
• Villapiano, A. J. 1998. Time-managed group psychotherapy: Effective clinical applications. Psychiatric Services 49 (6):838–838. doi:10.1176/ps.49.6.838.
   Web of Science ®Google Scholar
• Wasson, R. G., and T. J. Riedlinger. 1990. The sacred mushroom seeker: Essays for R. Gordon Wasson. Vol. 4. Historical, ethno- & economic botany series. Portland, Oregon: Dioscorides Press.
   Google Scholar
• Watts, R., C. Day, J. Krzanowski, D. Nutt, and R. Carhart-Harris. 2017. Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology 57 (5):520–64. doi:10.1177/0022167817709585.
   Web of Science ®Google Scholar
• Zinberg, N. E. 1984. Drug, set, and setting: The basis for controlled intoxicant use. New Haven: Yale University Press.
   Google Scholar